Adam Shpigel, MD
Interventional Cardiology · Saint Louis, MONPI 1417223447
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (52.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Medtronic at 58.8% of the total. Reporting peaked in 2019 at $21,704 and has fallen 87.6% since, to $2,686 in 2025.
Across 501 payments — averaging $68.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Abbott$2K
- Edwards Lifesciences$2K
- Boston Scientific$2K
- Abiomed$1K
- Amgen$964
- plus $6K from 31 others
What the payments were for
- Grants$18,00052%
- Travel & lodging$3,37310%
- Food & beverage$13,09638%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $20,262 |
| Abbott | 29 | $2,344 |
| Edwards Lifesciences | 41 | $2,109 |
| Boston Scientific | 44 | $1,783 |
| Abiomed | 20 | $1,193 |
| Amgen | 52 | $964 |
| Novartis | 55 | $931 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 40 | $826 |
| Shockwave Medical, Inc | 45 | $779 |
| Philips North America LLC | 6 | $437 |
| Johnson & Johnson | 22 | $375 |
| Boehringer Ingelheim | 17 | $356 |
| Chiesi USA, Inc. | 17 | $297 |
| Cardiovascular Systems Inc. | 12 | $260 |
| AstraZeneca | 16 | $244 |
| Pfizer | 11 | $225 |
| Kestra Medical Technology Services, Inc. | 7 | $126 |
| Merck | 6 | $105 |
| Amarin Pharma, Inc. | 6 | $104 |
| Alnylam Pharmaceuticals Inc. | 4 | $88 |
| Livanova USA, Inc. | 1 | $68 |
| Scpharmaceuticals Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Cardiva Medical, Inc. | 3 | $59 |
| Inari Medical, Inc. | 3 | $52 |
| Lantheus Medical Imaging, Inc. | 2 | $51 |
| Heartflow, Inc. | 2 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $43 |
| Bayer | 2 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $29 |
| Biotronik Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| ZOLL Circulation Inc | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Cook Medical LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$19,603
- MitraClip$975
- Edwards SAPIEN 3 Transcatheter Heart Valve$772
- Xience Sierra Coronary Stent System$539
- IGT D Coronary$262
- GENERAL - STENTS$235
- SYMPLICITY G3$173
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$167
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$139
- WATCHMAN Access System$136
- Coronary Orbital Atherectomy System$125
- Impella$117
- Trilogy 100$115
- SYNERGY$114
- Optis Coronary Imaging System$109
How this compares
$34,469 in reported general payments places this provider in the 80th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 425 | $429,061 |
| EntrestoSacubitril/Valsartan | 137 | $121,075 |
| Repatha SureclickEvolocumab | 115 | $95,300 |
| XareltoRivaroxaban | 64 | $78,234 |
| BrilintaTicagrelor | 50 | $41,534 |
| FarxigaDapagliflozin Propanediol | 31 | $37,044 |
| Repatha SyringeEvolocumab | 33 | $28,853 |
| MultaqDronedarone Hcl | 14 | $23,327 |
| Metoprolol Succinate | 558 | $6,706 |
| Atorvastatin Calcium | 488 | $5,698 |
| Rosuvastatin Calcium | 406 | $4,477 |
| Ranolazine ErRanolazine | 29 | $4,149 |
| Ezetimibe | 228 | $3,943 |
| ClopidogrelClopidogrel Bisulfate | 363 | $3,206 |
| Losartan Potassium | 269 | $2,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $225 | $429,061425 claims |
| NovartisEntresto | $931 | $121,075137 claims |
| AstraZenecaBrilinta, Farxiga | $244 | $78,57981 claims |
| Johnson & JohnsonXarelto | $375 | $78,23464 claims |
| Sanofi-aventis U.S. LLCMultaq | $22 | $23,32714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Saint Louis
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
- Prashanth ThakkerSaint Louis$129K
- Marc SintekSaint Louis$119K
- George KichuraSaint Louis$118K
- Gil VardiSaint Louis$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.